Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ISU304 in Hemophilia B
NCT03186677Phase 1Completed
- Sponsor
- ISU Abxis Co., Ltd.
- Start
- Jun 2017
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of dalcinonacog alfa in hemophilia B (HB) (5 cohorts), sponsored by ISU Abxis Co., Ltd. Primary endpoint: Number of Adverse Events (AEs) After the Administration of Investigational Products. Started Jun 2017; status: completed.
02
Drugs
dalcinonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT03186677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03186677.